In a report published Friday, Cantor Fitzgerald reiterated its Buy rating on CVS Caremark Corporation CVS, and raised its price target from $55.00 to $57.00.
Cantor Fitzgerald noted, “Despite some concerns over what CVS could possibly do for an encore following some exceptional tailwinds in 2012, the combination of a major dividend increase and very strong (above consensus) EPS guidance set the tone for a very upbeat analyst meeting. We liked what we heard in the management presentations and have greater conviction in our 2013 earnings outlook. We reiterate our BUY rating with a revised price target is $57 (from $55).”
CVS Caremark Corporation closed on Thursday at $48.50.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in